Immunotherapy to Treat Cancer

Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach

(2016) X Chen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy

(2016) AS Mansfield et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy

(2016) LC Villaruz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Immune-Related Adverse Events From Immune Checkpoint Inhibitors

(2016) KA Marrone et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies

(2016) CJ Turtle et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Checkpoint inhibitors

(2016) Jean A. Klastersky   CURRENT OPINION IN ONCOLOGY

Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer

(2016) Scott D. Ramsey et al.   JOURNAL OF CLINICAL ONCOLOGY

Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Overspending driven by oversized single dose vials of cancer drugs

(2016) Peter B Bach et al.   BMJ-British Medical Journal

Overspending driven by oversized single dose vials of cancer drugs

(2016) Peter B Bach et al.   BMJ-British Medical Journal

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Immune Checkpoint Blockade in Cancer Therapy

(2015) James P. Allison   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models

(2013) Sirus Palsson et al.   BMC Systems Biology